Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years

Key Points Patients with t-MDS are underrepresented in clinical trials when taking into account the prevalence of such patients. Eligibility criteria and sponsorship type may contribute to t-MDS patient exclusion.